Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23152768 | 0.94 | EGFR (0.61) | EGFR | |
| SCHEMBL23152889 | 0.93 | EGFR (0.69) | EGFR | |
| SCHEMBL23178812 | 0.88 | EGFR (0.61) | EGFR | |
| SCHEMBL24687685 | 0.87 | EGFR (0.63) | EGFR | |
| SCHEMBL23152824 | 0.86 | EGFR (0.71) | EGFR | |
| SCHEMBL23152913 | 0.85 | EGFR (0.60) | EGFR | |
| SCHEMBL23152849 | 0.85 | EGFR (0.68) | EGFR | |
| SCHEMBL23152907 | 0.84 | EGFR (0.59) | EGFR | |
| SCHEMBL23152840 | 0.83 | EGFR (0.63) | EGFR | |
| SCHEMBL23152870 | 0.83 | EGFR (0.62) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027026-A1 | FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027026-A1 | FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | DPYD, TYMP, TYMS | EGFR 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.